


RESEARCH

Open Access



Imported and autochthonous malaria in West Saudi Arabia: results from a reference hospital

Rasha Hassan Soliman^{1,2}, Patricia Garcia-Aranda³, Sherine Mohamed Elzagawy^{2,4}, Boshra El-Sayed Hussein^{5,6}, Wael Wahid Mayah^{5,7}, Alexandra Martin Ramirez³, Thuy-Huong Ta-Tang³ and José Miguel Rubio^{3*} 

Abstract

Background: The Kingdom of Saudi Arabia is seeking malaria eradication. Malaria transmission has been very low over the last few years. Discovered cases of *Plasmodium falciparum* infection are assigned a treatment protocol of artemisinin-based combination therapy, which consists of artesunate in addition to sulfadoxine-pyrimethamine rather than the traditional chloroquine, which has high resistance rates worldwide. This study aims to investigate the presence of different gene mutations concerning anti-malarial drug resistance (*pfdhfr*, *pfdhps*, *pfmdr1*, *pfcr1*, *pfcytb*, *pfketch13*) to identify whether drug-resistant alleles are present in this area of the Kingdom and whether the country's treatment protocol is still suitable for *Plasmodium* bearing a resistance mutation.

Methods: Blood samples were collected from patients suffering from symptoms suggesting malaria coming to King Faisal Hospital, Taif, from February to August 2016. Diagnosis was performed by Giemsa-stained thin and thick blood films, rapid diagnostic test and PCR. Positive *P. falciparum* samples were further subjected to series of PCR amplification reactions targeting genes related with drug resistance (*pfdhfr*, *pfdhps*, *pfmdr1*, *pfcr1*, *pfcytb*, *pfketch13*).

Results: Twenty-six cases were positives, 13 infected with *P. falciparum*, of those, 4 cases were autochthonous, and 13 with *Plasmodium vivax*. The results of the gene mutation detection confirmed that there was no mutation related to resistance to artemisinin or atovaquone, on the other hand chloroquine resistance alleles were detected in 31% of samples. Moreover, point mutations in the *pfdhfr* and *pfdhps* genes, related resistance to antifolate drugs, were detected in all characterized samples.

Conclusions: Haplotypes of *P. falciparum* in the western region of the Kingdom of Saudi Arabia exhibit high resistance against antifolate drugs. These results should be extensively discussed when planning to modify anti-malarial drug protocols in the future.

Keywords: *Plasmodium falciparum*, Drug resistance, Antifolate drugs, Saudi Arabia, Indigenous cases

Background

Malaria is considered one of the main ongoing causes of morbidity and mortality globally, affecting vulnerable groups, such as pregnant women and children [1]. This major health hazard is equally encountered in countries

with regular transmission as well as those where transmission has been largely controlled or eliminated [2].

The Arabian Peninsula stretches out at the fringes of malaria endemicity where disease transmission has undergone different stages of reduction as a consequence of continuous vector control efforts. In Saudi Arabia, the biggest country in the gulf area with more of 32 million inhabitants, malaria was a noteworthy health issue in the middle of the last Century with frequent transmission all over the country, with 48,000 people living in foci areas

*Correspondence: jmrubio@isciii.es

³ Malaria and Emerging Parasitic Diseases Laboratory, National Microbiology Centre, Instituto de Salud Carlos III, Madrid, Spain
Full list of author information is available at the end of the article



[1]. Nevertheless, elimination of the disease in many regions was established in 1957 after the introduction of a systematic control programme based on dynamic case detection, enhanced surveillance and vector control, however, it remains sporadic and resilient in some areas [3–7]. Saudi Arabia is included in the E-2020 initiative by the World Health Organization (WHO), given a target of zero indigenous cases for 2020, but in the last published data, the country shows a rise in cases passing from 83 in 2015 to 272 in 2016 [1]. In addition, there are around 5000 imported malaria cases. *Plasmodium falciparum* counts for most of the cases of indigenous malaria, 270 in 2016, with sporadic cases of *Plasmodium vivax* (two in the last WHO report [1]).

According to malaria endemicity, Saudi Arabia can be partitioned into four topographical categories: (i) non-malarious areas lying in the centre of the country, where *Anopheles sergentii* is detected in low density and occasional imported cases may be reported; (ii) northern and eastern parts of the country where effective control measures resulted in termination of malaria transmission, but where *Anopheles superpictus* and *Anopheles stephensi* are still present as possible vectors; (iii) western part of the country with low malaria occurrence accounting for about 1–3 cases by 1000 inhabitants/year, where *An. sergentii* and *An. superpictus* are present; and, (iv) southern and southwestern parts of the country spread over the coastal plain along the Red Sea down to the border with Yemen and Tihama foothills with medium to high malaria incidence rates, where *An. sergentii* and *Anopheles arabiensis* are the main vectors [7, 8].

Even if malaria incidence is currently low, a large number of imported cases sustain potential for indigenous transmission [9]. There are three main sources of imported malaria in Saudi Arabia. The most important may be the huge number of pilgrims from around the world who visit Islamic holy places located in Saudi Arabia each year [10]. Also, the economic situation of the country is a magnet for workers in the surrounding malaria-endemic countries [11, 12] and, thirdly, the shared southern border with the Republic of Yemen, which is a malaria hyperendemic country with more than 50,000 cases notified in 2016 [1].

Controlling imported malaria becomes more crucial, especially as autochthonous endemicity has declined or even been eliminated in some areas [13], while the proportion of imported cases has expanded drastically. Imported malaria cases were accountable for 11.4% in 1998, and rose to 97.5 and 95% of malaria cases in 2011 and 2016, respectively [1, 9]. In a retrospective study, malaria was responsible for 3% of infectious disease admission to hospital in the western region of Saudi Arabia over a 5-year period [14]. Therefore, there is a clear

risk that human movement can re-introduce malaria into areas where elimination has been established, resulting in the emergence of outbreaks in Saudi Arabia [15].

For a long time, chloroquine was the first-line treatment of uncomplicated malaria in the southwest of Saudi Arabia. Nevertheless, the spread of chloroquine resistance has prompted the use of sulfadoxine-pyrimethamine (SP) treatment [16]. Lately, the health authority in Saudi Arabia has embraced artemisinin-based combination therapy (ACT), comprising artesunate in addition to SP for uncomplicated *P. falciparum* infection. In severe *P. falciparum* infections, artesunate, artemether and quinine are the treatments of choice. In cases of *P. vivax*, chloroquine plus 14 days of primaquine is the treatment of choice [1].

Due to the rapid expansion of resistance to anti-malaria drugs and the special circumstance of Saudi Arabia with millions of visitors from endemic areas, including Southeast Asia where resistance to artemisinins has been characterized, it is crucial to investigate the pattern of resistance genes that are present in indigenous and imported malaria cases in the different areas of Saudi Arabia, as control strategies based on these data will most definitely diminish the prevalence of drug resistance parasites and thus improve therapeutic management of malaria cases [17] and help to achieve malaria elimination in Saudi Arabia.

The aim of this study is to analyse malaria cases characterized in a reference hospital in Taif, a city close to Mecca in the west of Saudi Arabia with a low transmission malaria rate, and to identify the genes associated with resistance that are present in the region.

Methods

Patients and samples

Blood samples were collected from patients coming to King Faisal hospital, Taif, Kingdom of Saudi Arabia (KSA) during the period of 6 months from February to August 2016, suffering from symptoms suggesting malaria infection (episodes of fever, chills, sweating followed by episodes of normality) and/or symptoms and signs related to blood haemolysis. Patient consent was obtained prior to collecting blood samples. Ethical approval was obtained from Taif University Research Ethics Committee (number 38-36-0019).

Giemsa-stained thin and thick blood films were prepared and rapid diagnostic test (RDT) was performed to confirm the diagnosis [18]. Blood spots were collected at the same time for DNA extraction on Whatman's filter paper and each paper was separately saved in a sealed zip-lock plastic bag to avoid subsequent contamination. The personal data of each patient were registered including age, gender and nationality.

Molecular identification and genotyping

DNA extraction from blood spots was carried out using the QIAamp® DNA Mini Kit (QIAGEN, Germany). Two 5-sq mm blood spots were incubated at 56 °C overnight previous to DNA extraction following the manufacturer's instructions for DNA purification from tissues. Final elution volume was in 100 µl of distilled water and stored at 4 °C until use. Malaria diagnoses were validated with a modification of the nested multiplex malaria PCR (NM-PCR) based on the small sub-unit (SSU) rRNA genes [19, 20]. The method is able to identify the 4 human malaria species (*P. vivax*, *P. falciparum*, *Plasmodium ovale*, *Plasmodium malariae*) in 2 consecutive multiplexing amplifications.

Plasmodium falciparum drug resistance gene screening

Samples that were diagnosed as *P. falciparum* were further subjected to series of PCR amplification reactions targeting different genes related with drug resistance in *P. falciparum* (*pfdhfr*, *pfdhps*, *pfmdr1*, *pfcr*, *pfcytb*, *pfketch13*) according to their authors [21–24].

Amplified gene products were subsequently subjected to sequencing to assess the occurrence of significant mutations. The amplified products were purified using Illustra DNA and gel band purification kit (General Electric Healthcare) and sequenced with the Big Dye Terminator v3.1 cycle sequencing in an ABI PRISM®3700 DNA analyzer. All amplified products were sequenced in both directions twice.

Results

From all the suspected cases that were screened, 26 cases were diagnosed positive for malaria by microscopy and RDT. Multiplex PCR confirmed the diagnosis of these samples with 13 cases diagnosed as *P. falciparum* and 13 cases diagnosed as *P. vivax*. All the patients were males. The mean age of the patients was $28.1 \pm SD 8.15$ (24–32) years old. Different nationalities were represented among the patients of the study: Saudi, Sudanese, Ethiopian, Pakistani, Indian, and Nigerian (Table 1). Sudanese people represented 38.2% of the patients and had the highest number of *P. falciparum* (6 cases). Pakistani only presented infection by *P. vivax*, while 1 patient from Nigeria and 4 Saudi were infected by *P. falciparum*. The rest of nationalities had cases with both infections, but no mixed infections were characterized by microscopy or PCR. The 4 Saudi patients denied travelling abroad to malaria-endemic countries and they were considered as indigenous cases (Table 1). All positive *P. falciparum* samples showed wild type alleles for *pfcytb* and *pfketch13* genes. The *pfmdr-1* gene showed the N86Y mutation in 3 samples (23%) while no sample showed the mutation in the position 1246 of the gene (D1246Y). In 4 of the

Table 1 Nationality of malaria positive cases and species involved in the infection

| Nationality | <i>P. vivax</i> | <i>P. falciparum</i> | Total |
|-------------|-----------------|----------------------|-------|
| Sudanese | 4 | 6 | 10 |
| Pakistani | 5 | 0 | 5 |
| Indian | 3 | 1 | 4 |
| Saudi | 0 | 4 | 4 |
| Ethiopian | 1 | 1 | 2 |
| Nigerian | 0 | 1 | 1 |
| Total | 13 | 13 | 26 |

patients (31%), the triple mutation M74I, N75E, K76T for the *pfcr* gene was found.

Mutations in the *pfdhfr* gene were present in all samples, the triple mutation (N51I, C59R, S108N), which is related to SP resistance in vitro and in vivo, were detected in 9 samples (69%) and the double mutations (N51I, S108N) were detected in 3 samples (23%). For the *pfdhps* gene almost all the samples contained one or more of the recorded gene mutations (Table 2).

Regarding nationalities, *pfdhfr* and *pfdhps* are distributed in all countries, *pfmdr-1* N86Y was present in 2 out of 4 Saudi cases (50%) and in the Indian patient, and *pfcr* triple mutation was found in 2 out of 6 patients from Sudan (33,3%), in the Indian patient and in 1 out of 4 Saudi patients (25%). The Indian patient and one of the Saudi cases presented mutations in all genes except for *pfcytb* and *pfketch13*.

Discussion

The first step for malaria elimination is a correct diagnosis. The microscopic observation of thick blood film, as malaria diagnosis gold standard, is a good choice for diagnosis but it is a method sometimes very subjective and very dependent of qualification of the observer. On the other hand, RDTs are not specific and in general cannot differentiate between *P. falciparum* and mixed infections. PCR, however, avoids subjectivity and is highly specific. In this case, all PCR results were confirmed by microscopy, but RDT is not useful in a context where *P. falciparum* and *P. vivax* are present in equal proportions (unlike in the main areas in Africa where *P. falciparum* is clearly dominant).

One of the most important problems in malaria control is *P. falciparum* drug resistance due to the growing resistance to almost all anti-malarial drugs, including chloroquine, amodiaquine, mefloquine, SP, artemether–lumefantrine, and lately, artemisinin [25]. After a country decides to withdraw a specific drug as a consequence of the emergence of drug resistance, the resistant parasites augment in comparison to the sensitive ones. Moreover, when countries do not take that

Table 2 Mutations characterized in the different genes related to resistance to malaria drugs analyzed

| Sample number | Nationality | DHPS genotype | DHFR genotype | CytB genotype | MDR genotype | | CRT genotype | K13 genotype |
|---------------|-------------|---------------|-------------------|---------------|--------------|--------|------------------|--------------|
| | | | | | N86Y | D1246Y | | |
| 1 | Nigerian | S436A | N51I, C59R, S108N | Wild | Wild | Wild | Wild | Wild |
| 2 | Sudanese | S436A, K540E | N51I, C59R, S108N | Wild | Wild | Wild | M74I, N75E, K76T | Wild |
| 3 | Saudi | S436A | N51I, C59R, S108N | Wild | Wild | Wild | Wild | Wild |
| 6 | Ethiopian | K540E | N51I, C59R, S108N | Wild | Wild | Wild | Wild | Wild |
| 10 | Saudi | K540E | N51I, S108N | Wild | N86Y | Wild | Wild | Wild |
| 15 | Sudanese | S436A | N51I, C59R, S108N | Wild | Wild | Wild | Wild | Wild |
| 16 | Sudanese | S436A | N51I, C59R, S108N | Wild | Wild | Wild | Wild | Wild |
| 17 | Saudi | K540E, A581G | N51I, C59R, S108N | Wild | Wild | Wild | Wild | Wild |
| 18 | Sudanese | NA | NA | NA | NA | Wild | Wild | NA |
| 19 | Sudanese | S436A | N51I, C59R, S108N | Wild | Wild | Wild | M74I, N75E, K76T | Wild |
| 20 | Indian | S436A, K540E | N51I, S108N | Wild | N86Y | Wild | M74I, N75E, K76T | Wild |
| 21 | Sudanese | A437G | N51I, S108N | Wild | Wild | Wild | Wild | Wild |
| 26 | Saudi | – | N51I, C59R, S108N | Wild | N86Y | Wild | M74I, N75E, K76T | Wild |

NA no amplification was obtained after several trials

decision as soon as drug resistance is confirmed, the mutations become permanent in the population and the possibility of using this drug as a treatment or as a prophylaxis is excluded [25]. As the KSA is actively seeking to eliminate malaria [26], molecular markers that can detect anti-malarial drug resistance represent one of the most important methods in screening for anti-malarial drugs. Markers can forecast the resistance and effectiveness to anti-malarial drugs, and point out emerging resistance in a specific area [27].

As one of the vibrant cities of the Kingdom and closely adjacent to the holy city of Mecca, where millions of pilgrims arrive every year, all year round, Taif represents a strong contender to be a focus for malaria in the Kingdom. King Faisal Hospital in Taif received 26 confirmed malaria cases over the period of 6 months (February to August 2016) of which 50% were diagnosed and then confirmed as *P. falciparum* infection. Although it is usually believed that the majority of malaria cases encountered now in the Kingdom are imported [28], 4 cases were Saudi and all of them were diagnosed as *P. falciparum*. This is an alarming reminder for the health authorities that malaria cases should not only be suspected in travellers or immigrants.

This study aimed to shed a light on probable emerging anti-malarial drug resistance in this area through the discovery of different mutations of significant genes. As the *pficytb* and *pfketch13* genes in all of the samples were wild type, this suggests that using atovaquone or artemisinin as anti-malarial drug harbours no risk of resistance in the Taif area for now. On the other hand, the triple mutation in the *pfprt* gene was observed in the 25% of the samples

with the K76T mutation, which is the key observation in chloroquine-resistant haplotypes. Numerous studies have identified the K76T mutation as the central factor in chloroquine resistance development [25, 29–31], occurring through the replacement of lysine amino acid (K) by threonine (T) [29]. This mutation is present in all chloroquine resistance isolates from different malaria-endemic regions and can consistently be used as a chloroquine resistance marker either alone or combined with other *pfprt* mutations. It is believed that *P. falciparum* mostly utilizes a mutant *pfprt* product to increase efflux of chloroquine from the parasite digestive vacuole [32].

Two samples, from India and Saudi Arabia, carried a combination of mutations in the *pfmdr1* and *pfprt* genes (N86Y + K76T), which are related to resistance to both chloroquine and amodiaquine. The N86Y substitution has been mentioned as a chloroquine modulator [33] and it is believed to be related to parasite fitness adaptation in reaction to physiological changes from *pfprt* point mutations [34]. KSA now follows a policy using ACT, instead of the traditional chloroquine therapy, using artesunate plus SP as first-line or artemether plus lumefantrine as second-line treatment of uncomplicated *P. falciparum* [35]. SP was substituted to chloroquine as the first-line drug against malaria in some countries, but was later suspended as a consequence of the rapid occurrence of parasite resistance, but it remains valuable for intermittent preventive treatment (IPT) during pregnancy [36].

Point mutations in the *pfdhfr* and *pfdhps* genes are the chief reasons for resistance to antifolate drugs in *P. falciparum*. Point mutations affecting *pfdhfr* bestow pyrimethamine resistance, a point mutation changing Ser108 to Asn108 (S108N) in the *pfdhfr* gene increases

resistance to pyrimethamine about 100-fold [37]. All the amplified samples for this gene (100%) contained the S108N mutation. Moreover, 9 out of 12 samples (75%) exhibited the triple mutation (N51I, C59R, S108N, haplotype IRN), which is a critical marker for pyrimethamine resistance, and subsequent SP failure [25, 37]. These results confirm a recent study from the southwestern region of KSA reporting the presence of the triple mutation [38].

Changes in 5 different amino acids have been observed in *pf dhps* in laboratory reference isolates: Ser436 to Ala or Phe (S436A/F), Ala437 to Gly (A437G), Lys540 to Glu (K540E), Ala581 to Gly (A581G), and Ala613 to Ser or Thr (A613S/T). No mutations have so far been described outside of these 5 codons and they were established to associate with the increase resistance to sulfadoxine and a number of other sulfonamides [37]. In the present study, all 5 mutations were found in different combination of one, 2 and sometimes 3 different mutations in the same sample (Table 2). Accumulations of mutations in *pf dhps* gene are linked with increasingly lowered sensitivity to sulfonamides [38].

Based on the findings of this research, one can anticipate the failure of SP treatment in all these cases. But in clinical observation, only 2 cases were not responsive to first-line treatment encountered (artesunate plus SP) and were then shifted to second-line treatment (artemether plus lumefantrine). The 2 patients, number 6 and 16, had the triple mutation (N51I, C59R, S108N) in the *pf dhfr* gene, while they carried the K540E or S436A in the *pf dhps* gene (Table 2). The correlation of the parasite genotype to the effect of SP treatment in a patient is affected by many factors and the parasite genotype is merely one of them. The immune response and the nutritional status of the host, along with the rates of drug metabolism and the complexity of the parasite infection, are all crucial in establishing whether a patient will overcome the infection [37]. Moreover, none of the samples showed any K13 gene mutations related to artemisinin derivatives resistance, thus the combination therapy (SP plus artesunate) can still be effective in the other patients and they even resolve the fever and other clinical manifestations.

Unfortunately, these patients risk having some resistant parasites that might overcome the drug action, continue at a low concentration for a period and then inflect a new episode. On the other hand, other researchers concluded that in case of high-grade resistance to SP treatment, failure rates are high even in the absence of artemisinin resistance [39]. When parasites contain a completely sensitive allele of *pf dhfr*, it is believed that the patient will drastically respond to SP treatment regardless of the *pf dhps* allele present. Otherwise, when a triple mutant allele of *pf dhfr* is carried, clinical failure is to be expected,

and it becomes more than ever anticipated if the quadruple-mutant allele is present. In this sense, the clinical effect established will be reliant on the *pf dhfr* and *pf dhps* alleles of the parasite and the individual response of the patient [37].

It is now more than a decade since the speedy appearance of lumefantrine tolerance, subsequent to artemether and lumefantrine combination treatment, was described, and now this phenotype has been reported in many endemic areas. These parasites can survive in sub-therapeutic concentrations of lumefantrine. Studies had confirmed that these phenotypes are correlated with wild-type *pf mdr1* N86Y and wild-type *pf crt* K76T, alleles associated with chloroquine sensitivity [40]; this inverse relationship between lumefantrine and chloroquine susceptibility clarifies why lumefantrine is noted to be more efficient in parts of the world with chloroquine resistance. These lumefantrine-tolerant parasites would form the background for emergence of lumefantrine resistance [40]. Accordingly, the possibility of emergence of lumefantrine in the area of the study should be always cautiously anticipated as the percentage of *pf crt* and *pf mdr1* wild-type genes in the samples were by far more than the mutant ones.

Although it is not conventional to change chemotherapeutic recommendations depending on molecular studies alone, it is hoped that the recognition of early markers of resistance will enhance more extensive employment of reasonable treatment policies that will delay the appearance of drug resistance against different anti-malarial drugs.

Conclusion

The results show that haplotypes of *P. falciparum* in the western region of Saudi Arabia are exhibiting high resistance to SP. This finding would support making the decision to modify the first-line of treatment with other anti-malarial drugs, but this should be addressed after repeating the same study on a larger scale to reinforce the conclusion of the present study.

Abbreviations

ACT: artemisinin-based combination therapy; IPT: intermittent preventive treatment; NM-PCR: nested multiplex malaria PCR; *pf dhfr*: dihydrofolate reductase; *pf dhps*: dihydropteroate synthase; *pf ketch13*: kelch-propeller domains; *pf mdr1*: multidrug resistance 1 gene; *pf crt*: chloroquine resistance transporter; *pf cytb*: cytochrome-b; RDT: rapid diagnostic test; SP: sulfadoxine-pyrimethamine.

Authors' contributions

RHS and JMR designed the study, BEH and WWM clinically diagnosed, treated, followed up of the patients and collected the samples, SME performed the parasitological diagnosis, PGA, AMR and THT performed molecular diagnosis and resistance sample characterization and analysis, and finally RHS,

THT and JMR wrote the manuscript. All authors read and approved the final manuscript.

Author details

¹ Microbiology Department, Faculty of Medicine, Taif University, Al Hawiyah, Taif, Kingdom of Saudi Arabia. ² Parasitology Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt. ³ Malaria and Emerging Parasitic Diseases Laboratory, National Microbiology Centre, Instituto de Salud Carlos III, Madrid, Spain. ⁴ Princes Nourah Bint Abdulrahman University, Riyadh, Kingdom of Saudi Arabia. ⁵ Department of Tropical Medicine and Infectious Diseases, Faculty of Medicine, Tanta University, Tanta, Egypt. ⁶ King Faisal Medical Complex, Taif, Kingdom of Saudi Arabia. ⁷ Faculty of Dentistry, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.

Acknowledgements

The authors are grateful to the staff of all institutions from Saudi Arabia, Egypt and Spain whose have contributed to this study.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Patient's consent was obtained prior to collecting blood samples. Ethical approval was obtained from Taif university research ethics committee under the number 38-36-0019.

Funding

This work was partially supported by the Spanish Strategic Health Action (AES-HSCIII) Grant Number P114CIII/00014.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 13 April 2018 Accepted: 1 August 2018

Published online: 07 August 2018

References

- WHO. Malaria world report 2017. Geneva: World Health Organization; 2018.
- Simon-Oke IA, Obimakinde ET, Afolabi OJ. Prevalence and distribution of malaria, *pfcr*t and *pfmdr* 1 genes in patients attending FUT Health Centre, Akure, Nigeria. *Beni-Suef Univ J Basic Appl Sci*. 2018;7:98–103.
- Abdel-Hameed AA. Antimalarial drug resistance in the Eastern Mediterranean region. *East Mediterr Health*. 2003;9:492–508.
- Snow RW, Amratia P, Zamani G, Munda CW, Noor AM, Memish ZA, et al. The malaria transition on the Arabian Peninsula: progress toward a malaria-free region between 1960–2010. *Adv Parasitol*. 2013;82:205–51.
- Meleigy M. Arabian Peninsula states launch plan to eradicate malaria. *BMJ*. 2007;334:117.
- Al-Hamidhi S, Mahdy MAK, Idris MA, Bin Dajem SM, Al-Sheikh AAH, Al-Qahtani A, et al. The prospect of malaria elimination in the Arabian Peninsula: a population genetic approach. *Infect Genet Evol*. 2014;27:25–31.
- Al-Seghayer SM. Malaria control in the Kingdom of Saudi Arabia. *Saudi Epidemiol Bull*. 1996;3:4.
- Khater EI, Sowilem MM, Sallam MF, Ahammed AM. Ecology and habitat characterization of mosquitoes in Saudi Arabia. *Trop Biomed*. 2013;30:409–27.
- Karunaweera ND, Galappaththy GN, Wirth DF. On the road to eliminate malaria in Sri Lanka: lessons from history, challenges, gaps in knowledge and research needs. *Malar J*. 2014;13:59.
- Khan AS, Qureshi F, Shah AH, Malik SA. Spectrum of malaria in Hajj pilgrims in the year 2000. *J Ayub Med Coll Abbottabad*. 2002;14:19–21.
- Babiker HA, Abdel-Muhsin AM, Ranford-Cartwright LC, Satti G, Walliker D. Characteristics of *Plasmodium falciparum* parasites that survive the lengthy dry season in eastern Sudan where malaria transmission is markedly seasonal. *Am J Trop Med Hyg*. 1998;59:582–90.
- Bruce MC, Donnelly CA, Alpers MP, Galinski MR, Barnwell JW, Walliker D, et al. Cross-species interactions between malaria parasites in humans. *Science*. 2000;287:845–8.
- Cotter C, Sturrock HJ, Hsiang MS, Liu J, Phillips AA, Hwang J, et al. The changing epidemiology of malaria elimination: new strategies for new challenges. *Lancet*. 2013;10:6736.
- Alghamdi AA. Pattern of infectious diseases in the western region of Saudi Arabia; a study of 495 hospitalized patients. *JKAU Med Sci*. 2009;16:3–15.
- Cohen JM, Smith DL, Cotter C, Ward A, Yamey G, Sabot OJ, et al. Malaria resurgence: a systematic review and assessment of its causes. *Malar J*. 2012;11:122.
- Ghanchi NK, Ursing J, Beg MA, Veiga MI, Jafri S, Mårtensson A. Prevalence of resistance associated polymorphisms in *Plasmodium falciparum* field isolates from southern Pakistan. *Malar J*. 2011;10:18.
- Al-Farsi HM, Al-Hashami ZS, Bin Dajem SM, Al-Sheikh AAH, Al-Qahtani A, Beja-Pereira A, et al. Source of drug resistant *Plasmodium falciparum* in a potential malaria elimination site in Saudi Arabia. *Infect Genet Evol*. 2012;12:1253–9.
- Abdel-Wahab MM, Ismail KA, El-Sayed NM. Laboratory diagnosis of malaria infection in clinically suspected cases using microscopic examination, optimal rapid antigen test and PCR. *PUJ*. 2012;5:59–66.
- Rubio JM, Post RJ, van Leeuwen WD, Henry M-C, Lindergard G, Hommel M. Alternative polymerase chain reaction method to identify *Plasmodium* species in human blood samples: the semi-nested multiplex malaria PCR (SnM-PCR). *Trans R Soc Trop Med Hyg*. 2002;96:S199–204.
- Ta TH, Hisam S, Lanza M, Jiram AI, Ismail N, Rubio JM. First case of a naturally acquired human infection with *Plasmodium cynomolgi*. *Malar J*. 2014;13:68.
- Duraisingh MT, Curtis J, Warhurst DC. *Plasmodium falciparum*: detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. *Exp Parasitol*. 1998;89:1–8.
- Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K, Cheng Q. Mutations in *Plasmodium falciparum* cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. *Antimicrob Agents Chemother*. 2000;44:2100–8.
- Happi TC, Thomas SM, Gbotosho GO, Falade CO, Akinboye DO, Gerena L, et al. Point mutations in the *pfcr*t and *pfmdr*-1 genes of *Plasmodium falciparum* and clinical response to chloroquine, among malaria patients from Nigeria. *Ann Trop Med Parasitol*. 2003;97:439–51.
- Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant *Plasmodium falciparum* malaria. *Nature*. 2014;505:50–5.
- Berzosa P, Esteban-Cantos A, García L, González V, Navarro M, Fernández T, et al. Profile of molecular mutations in *pfdhfr*, *pf dhps*, *pfmdr*1, and *pfcr*t genes of *Plasmodium falciparum* related to resistance to different anti-malarial drugs in the Bata District (Equatorial Guinea). *Malar J*. 2017;16:28.
- Coleman M, Al-Zahrani MH, Coleman M, Hemingway J, Omar A, Stanton MC, et al. A country on the verge of malaria elimination—the Kingdom of Saudi Arabia. *PLoS ONE*. 2014;9:e105980.
- Kateera F, Nsobya SL, Tukwasibwe S, Hakizimana E, Mutesa L, Mens PF, et al. Molecular surveillance of *Plasmodium falciparum* drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda. *Acta Trop*. 2016;164:329–36.
- Ministry of Health. The national policy of malaria case management in the Kingdom of Saudi Arabia. Riyadh: Abakar Printing Co.; 2008.
- Fidock DA, Namura T, Tally AK, Cooper RA, Dzekunov SM, Ferdig MT, et al. Mutations in *Plasmodium falciparum* digestive vacuole transmembrane protein, *pfcr*t and evidence for their role in chloroquine resistance. *Mol Cell*. 2000;6:861–71.
- Sidhu A, Verdier-Pinard D, Fidock A. Chloroquine resistance in *Plasmodium falciparum* malaria parasites conferred by *pfcr*t mutations. *Science*. 2002;4:210–3.

31. Atroosh WM, Al-Mekhlafi HM, Al-Jasari A, Sady H, Dawaki SS, Elyana FN, et al. Different patterns of *pfcr* and *pfmdr1* polymorphism in *Plasmodium falciparum* isolates from Tehama region, Yemen. *PeerJ*. 2016;4:e2191.
32. Roepe DP. *Pfcr* mediated drug transport in malarial parasites. *Biochemistry*. 2011;50:163–71.
33. Djimdé A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourté Y, et al. A molecular marker for chloroquine-resistant falciparum malaria. *N Engl J Med*. 2001;344:257–63.
34. Wellem TE, Plowe CV. Chloroquine-resistant malaria. *J Infect Dis*. 2001;184:770–6.
35. Nzila A, Al-Zahrani I. Drugs for the treatment of malaria in the Kingdom of Saudi Arabia. *Saudi Med J*. 2013;34:569–78.
36. Volkman SK, Herman J, Lukens AK, Hartl DL. Genome-wide association studies of drug-resistance determinants. *Trends Parasitol*. 2017;33:214–30.
37. Sibley CH, Hyde JE, Sims PF, Plowe CV, Kublin JG, Mberu EK, et al. Pyrimethamine–sulfadoxine resistance in *Plasmodium falciparum*: what next? *Trends Parasitol*. 2001;17:570–1.
38. Sibley CH. Understanding drug resistance in malaria parasites: basic science for public health. *Mol Biochem Parasitol*. 2014;195:107–14.
39. Dondorp AM, Smithuis FM, Woodrow C, von Seidlein L. How to contain artemisinin- and multidrug-resistant falciparum malaria. *Trends Parasitol*. 2017;33:353–63.
40. Sisowath C, Strömberg J, Mårtensson A, Msellem AM, Obondo C, Björkman A, et al. In vivo selection of *Plasmodium falciparum pfmdr1* 86N coding alleles by artemether–lumefantrine (Coartem). *J Infect Dis*. 2005;191:1014–7.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

